anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
To isolate individual organized constituents from animal or vegetable tissues or organs, e.g. in preparing active fractions from glands having internal secretion for example the thyroid gland and the pancreas, the tissues &c. are dried in a frozen state and powdered after which the coarser parts may, if desired, be separated from the finer parts, the desired constituent being finally isolated by treating successively with liquids of different specific gravity. The tissues may be frozen by means of the usual cooling media e.g. solid carbon dioxide and ether, or liquid air and the separating liquids may be chloroform containing for example 25, 20, 15, 10, and 5 per cent of ether and pure chloroform, a finer fractionation being carried out on the suspension containing the desired constituent. Examples are given of the isolation of muscle nuclei from beef and of colloid from the thyroid glands of pigs, the glands being frozen, dried in a sulphuric acid dessicator, treated to remove as far as possible the fat and connective tissue, ground and sifted and subjected to a double sedimentation in ether, the colloid being finally separated from the second sediment by centrifuging successively with mixtures of chloroform and ether.ALSO:To isolate individual organized constituents from animal or vegetable tissues or organs, e.g. in preparing active fractions from glands having internal secretion for example the thyroid gland and the pancreas, the tissues &c. are dried in a frozen state and powdered after which the coarser parts may if desired be separated from the finer parts, the desired constituent being finally isolated by treating successively with liquids of different specific gravity.  The tissues may be frozen by means of the usual cooling media, e.g. solid carbon dioxide and ether, or liquid air, and the separating liquids may be chloroform containing for example 25, 20, 15, 10 and 5 per cent of ether and pure chloroform, a finer fractionation being carried out on the suspension containing the desired constituent.  Examples are given of the isolation of muscle nuclei from beef and of colloid from the thyroid glands of pigs, the glands being frozen, dried in a sulphuric acid dessicator, treated to remove as far as possible the fat and connective tissue, ground and sifted, and subjected to a double sedimentation in ether, the colloid being finally separated from the second sediment by centrifuging successively with mixtures of chloroform and ether.
Hydroxyurea causes severe myelosuppression. Treatment with hydroxyurea should not be initiated if bone marrow function is markedly depressed. Bone marrow suppression may occur, and leukopenia is generally its first and most common manifestation. Thrombocytopenia and anemia occur less often and are seldom seen without a preceding leukopenia. Bone marrow depression is more likely in patients who have previously received radiotherapy or cytotoxic cancer chemotherapeutic agents; use hydroxyurea cautiously in such patients.

Evaluate hematologic status prior to and during treatment with hydroxyurea capsules. Provide supportive care and modify dose or discontinue hydroxyurea as needed. Recovery from myelosuppression is usually rapid when therapy is interrupted.
Ibuprofen tablets are contraindicated in patients with known hypersensitivity to ibuprofen.

Ibuprofen tablets should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. Severe, rarely fatal, anaphylactic-like reactions to NSAIDs have been reported in such patients [see Error! Hyperlink reference not valid., and Error! Hyperlink reference not valid.].

Ibuprofen tablets are contraindicated in the setting of coronary artery bypass graft (CABG) surgery [see Error! Hyperlink reference not valid.].
The invention discloses an application of a Schisandra sphenanthera Rehd.et Wils. extract in preparation of a medicament for treating a liver injury caused by acetaminophen (APAP). The main ingredients of the Schisandra sphenanthera Rehd.et Wils extract are schisantherin and deoxyschizandrin. Experiments find that the Schisandra sphenanthera Rehd.et Wils. extract can significantly resist serum ALT (alanine aminotransferase)and AST (aspartate amino transferase)level rise and necrosis of liver cells caused by the liver injury caused by APAP, and inhibits consumption of reductive glutathione in the liver cells, so as to relieve the liver injury degree caused by the APAP. The mechanism relates to activation of an Nrf2-ARE (NF-E2-related factor 2-antioxidative responsive element) signal channel, is manifested by raising mRNA (messenger Ribonucleic Acid) expression of Nrf2, facilitating Nrf2 nuclear translocation, starting a downstream medicament-metabolizing enzyme and transcribing an antioxidant gene. The experiment result shows that the Schisandra sphenanthera Rehd.et Wils. extract has a treatment effect on the liver injury caused by the APAP, and novel method and means are provided for clinical prevention and treatment of the liver injury caused by the APAP.
The invention relates to a system and method for tracking clients as they visit the locations of various recipients. Clients have access to telephones and identification devices which the client can use to communicate with a remote computer. The computer uses information received during the communication to identify and authenticate the client making the communication and the location of the client at the time of the communication. Authentication is accomplished by obtaining unique biometric parameters from a client over the phone and comparing those to biometric parameters in a database. Biometric data can include a voice print sampled during the call, or a finger or retinal print electronically transmitted during the call. Because each of these identifiers results from a physiological characteristic which is unique to the client, the system assures that the identified client is the client making the communication. The system can include logic for identifying the address of a cellular phone at the time a phone call is placed. The logic does not require an automatic number identification (ANI). In fact, the ANI of a cellular phone may not provide any location information because the phone itself is mobile. Instead the logic uses information provided by the cellular carrier to identify the origin of the call with regard to the cell stations receiving the call. Accordingly, the client can be tracked when the client is using a cellular phone to communicate with the computer.
Cancer-related inflammation, anti-cancer treatment and other cancer-related comorbidities are proposed to affect atrial remodeling, increasing the susceptibility of lung cancer patients for developing atrial fibrillation. Moreover, cancer is assumed to modify the risk of thromboembolisms and bleeding. An association between AF and malignancy has been reported but incompletely defined. The earliest publications of cancer predisposing to AF came in the 1940s-50s with reports of neoplastic cardiac infiltration or mechanical pressure on the heart, and with oncologic thoracic surgery. Subsequently, multiple studies have reported an increased risk of AF after cancer therapy with surgery (particularly thoracic) and chemotherapy. However, the prevalence of AF appears to be higher in patients with cancer at the time of diagnosis even before undergoing therapy. The emerging field of cardio-oncology has revealed that these seemingly disparate disease processes are intertwined, owing to the cardiovascular sequelae of anticancer therapies, shared risk factors that predispose individuals to both cardiovascular disease and cancer, as well the possible potentiation of cancer growth by cardiac dysfunction. Although direct oral anticoagulants (DOAC) seem to represent a safe and effective option, compared to Vitamin K antagonists (VKA), in this population, this statement is based mainly on observational studies and sub analyses of pivotal trials of the DOAC.
Vagal nerve stimulation at the highest intensity tolerated by the participant. Participants will self-administered at this intensity for 12 minutes each day over 4 weeks.
TRELEGY ELLIPTA has not been studied in subjects with hepatic impairment. Information on the individual components is provided below.

Fluticasone Furoate/Vilanterol

Fluticasone furoate systemic exposure increased by up to 3-fold in subjects with hepatic impairment compared with healthy subjects. Hepatic impairment had no effect on vilanterol systemic exposure. Use TRELEGY ELLIPTA with caution in patients with moderate or severe hepatic impairment. Monitor patients for corticosteroid-related side effects [see Clinical Pharmacology (12.3)].

Umeclidinium

Patients with moderate hepatic impairment (Child-Pugh score of 7-9) showed no relevant increases in Cmax or AUC, nor did protein binding differ between subjects with moderate hepatic impairment and their healthy controls. Studies in subjects with severe hepatic impairment have not been performed [see Clinical Pharmacology (12.3)].
Participants received epoetin alfa administered intravenously three times a week during hemodialysis for up to 37 weeks. For the first two weeks the dose of epoetin alfa was based on the dose at the time of screening. Beginning at week 3 dose changes may have occurred every 2 weeks according to the alternative dosing algorithm, where smaller, frequent dose adjustments were permitted based on six hemoglobin categories.
Bundle treatment after cardiac arrest. Meanwhile, use the NeuroTrac™ Multi-TENS transcutaneous electrical stimulator to provide an asymmetric biphasic pulse train with a frequency of 35 Hz, an amplitude of 20 mA and a pulse width of 300ms, which is on for 20 seconds and off for 50 seconds. The treatment lasts for 8 hours per day and the treatment course lasts for 14 days.
Cancer has excelled as a leading cause of mortality. It is particularly serious in the elderly due to increased risk of functional impairment and present comorbidities. The physical exercise appears as a promising intervention in the various stages of the treatment, mitigating the adverse effects in short- and long-term the oncologic treatment. Its regular practice after a diagnosis of breast cancer is associated with 40 % to 50 % lower rates of mortality. Produces metabolic and morphological changes that may make it an important option in the treatment, prevention, and recovery process of these patients. In this context the present study aims to verify the effectiveness of home exercise on quality of life and physical fitness of elderly undergoing treatment for breast cancer. This study it's a Randomized Clinical Trial. Data will be collected at the Department of Oncology at the Professor Fernando Figueira Integral Medicine Institute (IMIP), which serves patients in the public health system (SUS) from the metropolitan area of Recife, State of Pernambuco. will be held from March to December 2015. Will be studied elderly diagnosed with breast cancer undergoing treatment in the Adult Oncology Service of IMIP. For the analysis of means and frequencies, the investigators intend to use descriptive statistics and the results will be displayed in graphs and tables. For inferential statistical analysis, the investigators intend to use the Student's t test, or the Mann - Whitney test, according to the normality of the sample. For categorical variables, contingency tables are constructed of type 2x2. Chi-square tests of association with Yates correction and Fisher's exact test will be used. The risk ratio (RR) will be calculated as a measure of the relative risk of different outcomes according to the realization of one or another approach to exercise and control group. The Software Stata 12.0 will be used for data processing and will be accepted at p \< 0,05. The project meets the requirements of the National Board of Health and was approved by the IMIP Research Ethics Committee. Patients who agree to sign the Instrument of Consent will be included in the study.
INTRODUCTION: Cytomegalovirus (CMV) infection is associated with a poor prognosis after lung transplantation, and donor and recipient CMV serostatus is a risk factor for reactivation. CMV prophylaxis is commonly administered in the first year following transplantation to reduce CMV infection; however, the risk factors for long-term reactivation remain unclear. We investigated the timing and risk factors of CMV infection after prophylactic administration.
METHODS: This study was a retrospective review of the institutional lung transplantation database from June 2014 to June 2022. Data on patient characteristics, pretransplantation laboratory values, postoperative outcomes, and CMV infection were collected. Donor CMV-IgG-positive and recipient CMV-IgG-negative groups were defined as the CMV mismatch group.
RESULTS: During the study period, 257 patients underwent lung transplantation and received a prophylactic dose of valganciclovir hydrochloride for up to 1 y. CMV infection was detected in 69 patients (26.8%): 40 of 203 (19.7%) in the non-CMV mismatch group and 29 of 54 (53.7%) in the CMV mismatch group (P < 0.001). CMV infection after prophylaxis occurred at a median of 425 and 455 d in the CMV mismatch and non-CMV mismatch groups, respectively (P = 0.07). Multivariate logistic regression analysis revealed that preoperative albumin level (odds ratio [OR] = 0.39, P = 0.04), CMV mismatch (OR = 15.7, P < 0.001), and donor age (OR = 1.05, P = 0.009) were significantly associated with CMV infection.
CONCLUSIONS: CMV mismatch may have increased the risk of CMV infection after lung transplantation, which decreased after prophylaxis. In addition to CMV mismatch, low preoperative albumin level and donor age were independent predictors of CMV infection.
PRIMARY OBJECTIVES: I. To measure the 8-week disease control (CR + PR + SD) rate of therapy with STA-9090 in patients with metastatic pancreas cancer who have failed (either progressed or did not tolerate) one or two lines of prior therapy. SECONDARY OBJECTIVES: I. To determine response rate (by RECIST criteria v1.1). II. To determine overall survival. III. To evaluate the safety and toxicity profile in this patient population. TERTIARY OBJECTIVES: I. We will obtain from all patients blood samples pre and post therapy (after 1 week of therapy) and isolate serum for interrogation for a variety of biomarkers (eg AKT, Stat3, Caspase 3). OUTLINE: Patients receive Hsp90 inhibitor STA-9090 intravenous (IV) over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up every 4 weeks.
Patients with a histopathologically confirmed diagnosis of malignant paraganglioma or pheochromocytoma and either evidence of metastases or unresectability who meet the inclusion/exclusion criteria. Approximately 40 patients will be enrolled.
An apparatus, method, and system for the design, administration and implementation of a lifestyle management program. The lifestyle management system maximizes contact and enrollment rates of traditional lifestyle management. This is accomplished through the creation of a system that combines telephonic-delivered lifestyle management (i.e. traditional lifestyle management) with work-site based health center clinician (“trusted clinician”). The lifestyle management program is characterized by the involvement of a trusted clinician who actively participates in the program by being involved in the stratification process, the contact step and the process of creating and updating the patient's individualized care plan. Therefore, the lifestyle management program allows the clinician to be involved in both contact and enrollment phases of the program. The lifestyle management program further increases the efficiency of the program by improving overall health through behavior modification. The benefit of such a program is the reduction of health risk by effectively changing lifestyle behaviors which, in turn, allows employers administering the program to realize higher returns on their investment into such programs.
The Phase 1 clinical trial is designed as a single-center, open-label, non-randomized study to evaluate the safety, tolerability and immunogenicity of a two-dose schedule of rBV A/B in healthy volunteers at three ascending dosage levels, 5 ug, 10 ug and 20 ug serotype-specific antigen (10 ug, 20 ug and 40 ug total immunizing protein) in three dosing cohorts and a two-dose regimen (Day 0 and Day 28) of a formulation containing only antigens at the 40 ug total immunizing protein dosage level. Approximately 44 volunteers (11 per cohort) are expected to be enrolled. Cohorts will enroll consecutively beginning with the lowest dosage level. Volunteers in each cohort will receive a two injection series at the assigned dosage level given as a 0.5 mL intramuscular (i.m.) injection on Day 0 and Day 28. Potential volunteers for study participation will undergo qualification screening for this study during the 21 days prior to the date scheduled for vaccination. After successful completion of the informed consent process and all screening assessments, volunteers will be scheduled for vaccination. Volunteers will report acute adverse events daily for 28 days after each vaccination and return to the clinic at regular intervals according to the Schedule of Study Assessments with the last scheduled follow-up 168 days (± 7 days) after the initial vaccination (Day 0).
Data from pregnant women during pregnancy (including age, maternal history, liver function during pregnancy, HBV DNA in early pregnancy and before delivery, comorbidities and complications during pregnancy, antiviral use before and during pregnancy, and HBV infection status in fathers) Newborn birth data (including body length, weight, Apgar score, feeding status, hepatitis B vaccination, hepatitis B immunoglobulin use, HBsAg at birth and 7 months after birth, HBV DNA). The newborns born to HBV-infected pregnant women were divided into HBV DNA-negative group, low-viral group, and high-viral group according to HBV DNA status. The HBV infection status of these newborns was counted in July, and the different viral loads were tested. The impact of HBV mother-to-child transmission.
Control group attends the standard care of patients with ABI in HUS including all necessary outpatient rehabilitation visits. When available, neuropsychological rehabilitation typically takes 1-2 months among the study target group.
Subjects will receive one dose of pembrolizumab 200 mg. Approximately 3 weeks after the initial dose of pembrolizumab, subjects will undergo wide excision and sentinel lymph node (SLN) biopsy. Post-operatively, subjects will receive up to 1 year of adjuvant pembrolizumab 200 mg every 3 weeks.
Group II -16 patients undergoing general anaesthesia with endotracheal intubation, during the induction of anaesthesia the patients will be administered a muscle relaxant from the depolarising group (rocuronium, Esmeron®) for the endotracheal intubation procedure (using precurarisation). This is a method of pharmacological prevention of muscle fasciculation, characteristic of depolarising agents. For this purpose, a low-dose muscle relaxant from the non-depolarising group (rocuronium, Esmeron®) will be administered just before the actual dose of the depolarising agent. During the procedure itself, the level of relaxation will be continuously monitored by using the NMT - TOF % technique (a method of measuring neuromuscular excitability that allows real-time assessment of muscle strength). During the ablation performed, the patient will be under the influence of a muscle relaxant from the non-depolarising group (rocuronium, Esmeron®).
The present invention relates to a method of automatically classifying sleep stages through an existing deep neural network. A deep neural network, trained in advance by a user measuring electroencephalogram, automatically predicts a sleep stage. It is very time consuming for sleep experts to manually classify sleep stages, and to manually classify sleep stages is also expensive because all the various biological signals must be extracted. In addition, because the subjective judgment of sleep experts is the mainstay, accurate and stable sleep stage classification is not possible. The present invention relates to an automatic sleep stage classification system using electroencephalogram, comprising the steps of: measuring an electroencephalogram corresponding to a user's sleep state; performing frequency high-pass filtering to remove noise from the measured electroencephalogram; allowing classification of sleep stages by dividing the pre-processed electroencephalogram signal into 30-second increments; classifying, by a deep neural network, sleep stages for data divided into 30-second increments; and sending classified sleep stages to the user's computer monitor or smartphone. This method is much faster, more stable, more accurate, and cost-saving compared to the manual sleep stage classification of sleep experts.
FIELD: pharmaceutical industry. SUBSTANCE: agent has succinic acid bound with salbutamol in the form of complex - salbutamol hemisuccinate. New active substance is placed in semipermeable shell exhibiting the varying hole diameter to deliver an active component in patient organism and providing the varying dose of an active component in core. Agent shows the increased biological availability, decreased by-side effects, increased rate of effective concentration attainment and concentration level in organism. EFFECT: enhanced effectiveness of agent. 4 cl, 1 dwg, 1 tbl
The block of the sphenopalatine ganglion will be performed bilaterally through a cotton bud soaked with the anesthetic solution ropivacaine, at a concentration of 1%, advancing it through the nasal cavities towards the posterior nasopharynx wall. A slight resistance in the progression of the cottonoid indicates its contact with the mucosa of the posterior pharyngeal wall. The cottonoid will remain in this position for 20 minutes, so that there is absorption of the anesthetic solution through the mucosa up to the sphenopalatine ganglion, which, in general, is found anatomically around 3 millimeters in depth from the surface. After the established time, the cotton buds are removed.
This is a Phase 2 study of the combination of Ad-p53 administered intra-tumorally in combination with physician's choice of FDA approved immune checkpoint inhibitor therapy in patients with recurrent or metastatic cancers. This is a safety and efficacy study with a single cohort, consisting of the combination of Ad-p53 and infusions of immune checkpoint inhibitors. Immune checkpoint inhibitor treatments will be administered in accordance with FDA package inserts. Comparison will be made to historical data. General safety and preliminary efficacy will be determined using RECIST 1.1, ECOG status and Immune-Related Response Criteria. Biomarker testing of archival or fresh tissue is performed during the study. Enrollment will be up to 40 patients.